Vaccine Stratification and Monitoring

Solutions Accelerated by IsoPlexis

  • Vaccines & Immunology

Apply PSI as correlates to cancer vaccine patient survival and outcome

Discover biomarkers of response by uncovering functional immune cell subsets which correlate to outcome.

Download application highlight

Research Area

Development Stage

Predict

Goal

Identify enhanced polyfunctionality and PSI in after cancer vaccine treatment

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

IsoPlexis stratifies higher response rates based on PSI

polyfunctional cell

Finding

Upregulation of Polyfunctional strength ratio (PSR) was correlative to overall survival

follow our data

Follow Our Data

See the latest published data in Vaccines and Immunology Research

GVAX vaccination enhances polyfunctionality and PSI in CD4+ T cells of patients with pancreatic cancer. Polyfunctional CD4+ T cells were evaluated by 24-hour stimulation of anti-CD3/CD28.

An average increase of polyfunctional CD4+ T cells was detected in patients after GVAX treatment. The upregulated PSI of CD4+ T cells by the vaccine was predominated by effector proteins that are associated with antitumor immunity including Granzyme B, IFN-g, MIP-1a and TNF-b. The data was averaged from 5 patients.1

Download application highlight
CD4 PSI

Solution

Detect Critical Differences

Single-cell analysis identifies a significant association of CD4+ PSI fold change (post/pre vaccination) with overall survival (OS) of patients with pancreatic cancer after GVAX treatment. Blood was collected from patients before and 10-25 days after GVAX vaccination.

The post- versus pre-vaccination fold-change of PSI of CD4+ T cells was significantly associated with patient OS (P=0.001), indicating a potential of PSI in predicting GVAX vaccine efficacy and prognostic outcomes of patients.1

Significant association of single-cell CD4 PST to OS

Request a Seminar

Request a Seminar
Discover IsoLight